X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PIRAMAL ENTERPRISES GSK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 68.0 11.1 612.6% View Chart
P/BV x 13.7 1.9 715.9% View Chart
Dividend Yield % 2.1 0.9 246.8%  

Financials

 GSK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-18
GSK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,7603,083 89.5%   
Low Rs2,0401,902 107.3%   
Sales per share (Unadj.) Rs339.0589.7 57.5%  
Earnings per share (Unadj.) Rs41.4284.0 14.6%  
Cash flow per share (Unadj.) Rs45.9310.5 14.8%  
Dividends per share (Unadj.) Rs35.0025.00 140.0%  
Dividend yield (eoy) %1.51.0 145.4%  
Book value per share (Unadj.) Rs242.91,467.0 16.6%  
Shares outstanding (eoy) m84.70180.27 47.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x7.14.2 167.5%   
Avg P/E ratio x57.98.8 660.3%  
P/CF ratio (eoy) x52.38.0 651.3%  
Price / Book Value ratio x9.91.7 581.5%  
Dividend payout %84.58.8 960.1%   
Avg Mkt Cap Rs m203,280449,332 45.2%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m5,23419,881 26.3%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m28,715106,310 27.0%  
Other income Rs m5452,595 21.0%   
Total revenues Rs m29,260108,906 26.9%   
Gross profit Rs m5,05951,599 9.8%  
Depreciation Rs m3804,773 8.0%   
Interest Rs m229,783 0.0%   
Profit before tax Rs m5,22219,638 26.6%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892-28,764 -6.6%   
Profit after tax Rs m3,50851,203 6.9%  
Gross profit margin %17.648.5 36.3%  
Effective tax rate %36.2-146.5 -24.7%   
Net profit margin %12.248.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m21,815118,154 18.5%   
Current liabilities Rs m15,999462,260 3.5%   
Net working cap to sales %20.3-323.7 -6.3%  
Current ratio x1.40.3 533.5%  
Inventory Days Days6427 239.3%  
Debtors Days Days1947 40.2%  
Net fixed assets Rs m12,475113,727 11.0%   
Share capital Rs m847361 235.0%   
"Free" reserves Rs m19,726264,093 7.5%   
Net worth Rs m20,573264,454 7.8%   
Long term debt Rs m6242,206 0.0%   
Total assets Rs m39,475726,834 5.4%  
Interest coverage x2,612.01.7 157,410.1%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.70.1 497.3%   
Return on assets %8.911.1 79.8%  
Return on equity %17.119.4 88.1%  
Return on capital %26.210.3 254.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56415,110 3.7%   
Fx outflow Rs m7,4294,298 172.9%   
Net fx Rs m-6,86510,813 -63.5%   
CASH FLOW
From Operations Rs m4,728-159,666 -3.0%  
From Investments Rs m-1,042-17,677 5.9%  
From Financial Activity Rs m-3,066186,503 -1.6%  
Net Cashflow Rs m6209,364 6.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.0 255.0%  
FIIs % 23.8 26.6 89.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 16.5 93.3%  
Shareholders   102,036 93,274 109.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALEMBIC LTD  SUN PHARMA  IPCA LABS  FDC LTD.  AUROBINDO PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS